Recombinant sclerostin inhibits bone formation in vitro and in a mouse model of sclerosteosis

Recombinant sclerostin inhibits bone formation in vitro and in a mouse model of sclerosteosis

Background: Sclerosteosis, a severe autosomal recessive sclerosing skeletal dysplasia characterised by excessive bone formation, is caused by absence of sclerostin, a negative regulator of bone formation that binds LRP5/6 Wnt co-receptors. Current treatment is limited to surgical management of sympt...

Full description

Bibliographic Details
Main Authors: Timothy Dreyer, Mittal Shah, Carl Doyle, Kevin Greenslade, Mark Penney, Paul Creeke, Apoorva Kotian, Hua Zhu Ke, Vinny Naidoo, Gill Holdsworth
Format: Article
Language:English
Published: Elsevier 2021-07-01
Series:Journal of Orthopaedic Translation
Subjects:
Bone formation
Sclerosteosis
Sclerostin
SOST
Therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2214031X21000413

Internet

http://www.sciencedirect.com/science/article/pii/S2214031X21000413

Similar Items